Since C1-INH is known to inhibit fibrinolytic proteases plasmin and tPA, the therapeutic approach based on restoration of C1-INHlevels in the HAE-1 patients with administration of exogenous C1-INH is the main cause of the thromboembolic complications [85]. The gene discussed is PLG; the disease is hereditary angioedema with C1Inh deficiency.